What I said was one patient per site PER YEAR.
Facts:
> trevear sparsentan phase3 fgs trial got 371 patients
> from their paper, it took 33 months (April 2018 to Jan 2021) to screen & randomise the 371
> they operated in 225 sites, check the excellent interactive map on clinical trials. gov for their trial as proof
> my math tell me that’s 1.65 patients per site over 33 months or about 0.6 patients per site per year
so if anything dimerx is doing a bit better than traverea.
Ann: ACTION3 IND Approved in China, page-103
-
- There are more pages in this discussion • 129 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
52.5¢ |
Change
-0.015(2.78%) |
Mkt cap ! $288.8M | |||
| Open | High | Low | Value | Volume |
| 53.0¢ | 54.0¢ | 51.0¢ | $1.930M | 3.666M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 136 | 52.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 53.5¢ | 28650 | 2 |
View Market Depth
| Last trade - 16.10pm 18/07/2024 (20 minute delay) ? |
| DXB (ASX) Chart |